bioSyntagma logo — Eliminating trial-and-error cancer treatments through biomar...

bioSyntagma

Eliminating trial-and-error cancer treatments through biomarker discovery and predictive analytics

Founded 2015 United States Phoenix, United States 2 employees Grant Total: $1.38M Biotechnology, Life Sciences

General Information

Company Name bioSyntagma
Founded Year 2015
Location United States Phoenix, United States +2
Employees 2
Industries Biotechnology, Life Sciences
Funding Stage Grant
Social

Get notified when bioSyntagma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About bioSyntagma

bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. The company’s Molecular Fingerprint™ (mPrint™) platform creates a comprehensive, multi-omic and spatial profile of tissue to get a complete and informed understanding of the patient’s cancer so they can be matched with relevant therapies and recommended course of actions that prevent acquired drug resistance. bioSyntagma’s mPrint™ platform serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 19 Mar 2018
Grant •••••• 1
Investor
06 Feb 2018
Grant •••••• 1
Investor
01 Jan 2017
Grant •••••• - 05 Oct 2016

bioSyntagma Alternatives & Competitors

bioSyntagma vs
BostonGene
BostonGene United States

Transforming Cancer Care: From Treating a Diagnosis to Treating the Person

Series B
436 employees
Analytics, Health Care
bioSyntagma vs
BIOMAKERS
BIOMAKERS United States

Empowering Therapies with Precision Data

68 employees
Biopharma, Biotechnology
bioSyntagma vs
Tailor Bio
Tailor Bio United Kingdom

Pan-cancer precision medicine platform.

Seed
19 employees
AI, Health Care

FAQ About bioSyntagma

Eliminating trial-and-error cancer treatments through biomarker discovery and predictive analytics
bioSyntagma was founded in 2015.
bioSyntagma is headquartered in Phoenix, United States.
bioSyntagma operates in the following industries: Biotechnology, Life Sciences.
bioSyntagma has approximately 2 employees.
bioSyntagma has completed 4 funding rounds, raising a total of $1.38M. The latest funding stage is Grant.
Top alternatives and competitors to bioSyntagma include BostonGene, BIOMAKERS, Tailor Bio, Asylia Diagnostics BV, Akiram Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
bioSyntagma and BostonGene are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors bioSyntagma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy